Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
icosapent ethyl
|
| gptkbp:administrativeDivision |
twice daily
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availability |
gptkb:USA
|
| gptkbp:brand |
gptkb:Vascepa
|
| gptkbp:chemicalFormula |
C22H30O2
|
| gptkbp:clinicalTrials |
Phase 3
REDUCE-IT AHA/ACC guidelines adjunct to diet consider in high-risk patients proven in clinical trials |
| gptkbp:contraindication |
allergic reactions
hypersensitivity to icosapent ethyl |
| gptkbp:dosageForm |
1 gram
softgel |
| gptkbp:drugInterdiction |
omega-3 fatty acids
limited interactions highly bioavailable lipid-regulating agent reduces hepatic triglyceride production |
| gptkbp:formulation |
capsule
|
| gptkbp:hasPopulation |
adults
|
| gptkbp:healthcare |
important for efficacy
important for understanding use |
| gptkbp:historical_analysis |
VITAL study
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vascepa
|
| gptkbp:impact |
reduces risk of cardiovascular events
reduces triglycerides |
| gptkbp:interactsWith |
anticoagulants
antiplatelet drugs |
| gptkbp:is_monitored_by |
triglyceride levels
|
| gptkbp:mandates |
hypertriglyceridemia
|
| gptkbp:manufacturer |
gptkb:Amarin_Corporation
|
| gptkbp:marketedAs |
2012
|
| gptkbp:marketingStrategy |
2013
|
| gptkbp:offers |
varies by pharmacy
|
| gptkbp:packaging |
bottle
|
| gptkbp:patentExpiration |
2030
|
| gptkbp:regulatoryCompliance |
prescription only
|
| gptkbp:researchFocus |
cardiovascular health
|
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
black box warning
|
| gptkbp:sells |
gptkb:Vascepa
|
| gptkbp:sideEffect |
muscle pain
gastrointestinal issues increased risk of bleeding |
| gptkbp:storage |
room temperature
|
| gptkbp:supplyChain |
pharmaceutical distribution
|
| gptkbp:type |
icosapent ethyl
|
| gptkbp:usedFor |
lowering triglyceride levels
|
| gptkbp:weight |
330.47 g/mol
|